Re-evaluation of the effects of neuropeptide Y on aggregation of human platelets.
Several studies have shown that platelets are a major source of circulating neuropeptide Y (NPY) immunoreactivity in rats, but the effects of this vasoconstrictor peptide on platelets are not well-defined. Recently, it was reported that porcine NPY was an inhibitor of in vitro human platelet aggregation induced by epinephrine, an observation which would have important implications regarding platelet-vascular interactions during states involving platelet activation and thrombosis. Thus, we undertook the present studies, in an attempt to confirm the earlier report, and to extend those observations to human NPY. In contrast to the recent report, we found no inhibitory effect of either human or porcine NPY on epinephrine- or collagen-induced aggregation of human platelets from normal subjects. Likewise, specific NPY Y-1 and Y-2 agonists had no direct or indirect action on platelet aggregation. Finally, the effect of human NPY on intraplatelet cAMP was measured. The peptide had no effect on either basal or iloprost-stimulated cAMP levels. We hypothesize that the role of NPY in the platelet-vascular interaction is in promoting vasoconstriction associated with platelet aggregation, and does not include inhibition of further thrombosis.
Myers
A K
AK
Department of Physiology and Biophysics, Georgetown University Medical Center, Washington, DC 20007.
Abi-Younes
S
S
Zukowska-Grojec
Z
Z
D000328:Adult; D001792:Blood Platelets / Q000187:drug effects; D003094:Collagen / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D004837:Epinephrine / Q000494:pharmacology; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009478:Neuropeptide Y / Q000031:analogs & derivatives / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*
D009478:Neuropeptide Y; D003094:Collagen; D000242:Cyclic AMP; D004837:Epinephrine